The infusion center business makes up approximately half of the typical health system’s drug spend. While reimbursement for outpatient cancer drugs are generally favorable, most hospital outpatient department (HOPD) infusion centers struggle financially. Their financial sustainability is under increased threat due to recent changes to the 340B drug pricing program, emerging site-of-care policies from private payers, and rising drug prices.
Download this research briefing to learn about the basics of the changing HOPD business and the key challenges and opportunities IDNs are facing in this space. Arm yourself with insights on how you can respond and potentially partner with your IDN clients to navigate this financially-strained environment.